LAUSR

Entrectinib Effective across NTRK Fusion-Positive Cancers.

Sign Up to like & get
recommendations!
0 Published in 2019 at "Cancer discovery"

DOI: 10.1158/2159-8290.cd-nb2018-156

Abstract: Entrectinib may be an effective therapy for patients with NTRK fusion-positive solid tumors, regardless of tumor type. In a combined analysis of phase I and phase II trials, more than half of patients responded to… read more here.

Keywords: fusion positive; across ntrk; entrectinib effective; ntrk fusion ... See more keywords